Efficacy of Sintilimab Combined with Albumin Binding Type Paclitaxel and Cisplatin in the Treatment of EGFR Mutation Negative Non-small Cell Lung Cancer
Objective To investigate the efficacy of sintilimab combined with albumin binding type paclitaxel and cisplatin in the treatment of epidermal growth factor receptor(EGFR)mutation negative non-small cell lung cancer(NSCLC).Methods A total of 120 NSCLC patients with negative EGRF mutation(admitted from March 2021 to March 2023)were prospectively included and randomly divided into two groups.The control group received a combination of albumin binding type paclitaxel and cisplatin,while the observation group received an additional dose of sintilimab and received chemotherapy for three cycles,60 cases in each group.The efficacy and incidence of adverse reactions,levels of cell growth factor(VEGF),levels of tumor markers,and T lymphocyte subsets(CD4+,CD8+)were compared in both groups.Results Compared with control group,the clinical objective response rate of the observation group was higher(P＜0.05).After treatment,compared to the control group,the observation group had lower levels of cell growth factor indicators and tumor markers(P＜0.05).And the CD4+in the observation group was higher,while the CD8+was lower(P＜0.05).There was no difference in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion Sintilimab combined with albumin binding type paclitaxel and cisplatin in the treatment of EGFR mutated negative NSCLC can improve the overall chemotherapy effect,inhibit the generation of cytokines and the expression of tumor markers,reduce immune suppression caused by chemotherapy drugs,and do not increase drug toxicity.
NETL
NSTL
万方数据
